Gynecologic Cancer Trials

Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.

STUDY25269
A Phase I, First-in-human, Open-label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Patients With Advanced Solid Tumors

To determine the safety profile, and tolerability of BNT317 in patients with advanced solid tumors. To determine the MTD or the RP2D of BNT317 in patients with advanced solid tumors.

Study Information
STUDY26334
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors

To determine the RP2D of DB-1311 in combination with BNT327 by assessing the safety and tolerability in targeted participant populations. To determine the RP2D of DB-1311 in combination with DB-1305 by assessing the safety and tolerability in targeted participant populations.

Study Information
STUDY26716
An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer.

To demonstrate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd + pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by blinded independent central review (BICR), in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.

Study Information
STUDY26995
A Phase 1a/1b Study of NRM-823 as Monotherapy and in Combination with Immune Checkpoint Inhibition in Participants with Locally Advanced or Metastatic Refractory Solid Tumors

To determine the safety and tolerability of NRM-823 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors. To determine the recommended dose(s) for expansion (RDE)s of NRM-823 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors. The RDE may be the maximum tolerated dose (MTD) or a biologically active dose below the MTD.

Study Information
STUDY28126
A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer

To determine whether induction IO and chemotherapy prior to CCRT+IO improves progression-free survival (PFS) compared to CCRT+IO alone.

Study Information